/RAPT
RAPT Stock - RAPT Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$33.81-0.68%
$0.23 (-0.68%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+69.2%upside
Target: $57.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RAPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$33.47 – $34.15
TARGET (TP)$57.20
STOP LOSS$31.11
RISK/REWARD1:8.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.43
52W High$42.39
52W Low$5.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1.53M | $3.81M | $5.04M |
| Gross Profit | N/A | N/A | $1.53M | $3.81M | $5.04M |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-136,101,000 | $-127,062,000 | $-85,795,000 | $-69,209,000 | $-53,214,000 |
| Net Income | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 | $-52,892,000 |
| Net Margin | N/A | N/A | -5490.4% | -1814.9% | -1049.0% |
| EPS | $-25.49 | $-24.37 | $-20.61 | $-20.21 | $-17.53 |
Company Overview
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
53%
Hold / Neutral
9
47%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
10 Bullish9 Neutral/Bearish
Price Targets
$28
Average Target
↓ 16.6% Downside
Now
$2
Low
$28
Average
$70
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 27th 2025 | Guggenheim | Initiation | Buy | $70 |
| October 20th 2025 | JP Morgan | Upgrade | Overweight | $55 |
| October 13th 2025 | Barclays | Initiation | Overweight | $35 |
| September 26th 2025 | Leerink Partners | Upgrade | Outperform | $37 |
| July 30th 2025 | JP Morgan | Upgrade | Neutral | $14 |
| May 22nd 2025 | H.C. Wainwright | Resumed | Buy | $6 |
| December 26th 2024 | H.C. Wainwright | Upgrade | Buy | $10 |
| November 13th 2024 | Stifel | Downgrade | Hold | $2← $7 |
| November 11th 2024 | Piper Sandler | Downgrade | Neutral | $2← $8 |
| November 11th 2024 | JP Morgan | Downgrade | Underweight | - |
| May 14th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| May 10th 2024 | Guggenheim | Downgrade | Neutral | - |
| May 10th 2024 | Barclays | Downgrade | Equal Weight | $4← $13 |
| February 22nd 2024 | UBS | Downgrade | Neutral | $10← $61 |
| February 21st 2024 | Leerink Partners | Downgrade | Market Perform | $10← $42 |
Earnings History & Surprises
RAPTBeat Rate
56%
Last 18 quarters
Avg Surprise
-1.3%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q1 24
+5.9%
$-0.80vs$-0.85
Q2 24
-1.3%
$-0.79vs$-0.78
Q3 24
+4.1%
$-0.71vs$-0.74
Q4 24
+16.1%
$-0.47vs$-0.56
Q1 25
-153.3%
$-1.14vs$-0.45
Q2 25
+74.2%
$-0.64vs$-2.48
Q3 25
-6.6%
$-0.65vs$-0.61
Q4 25
+26.1%
$-0.65vs$-0.88
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.78 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.88 | $-0.65 | +26.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.61 | $-0.65 | -6.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-2.48 | $-0.64 | +74.2% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.45 | $-1.14 | -153.3% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.56 | $-0.47 | +16.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.74 | $-0.71 | +4.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.78 | $-0.79 | -1.3% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.85 | $-0.80 | +5.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.75 | $-0.82 | -9.3% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.80 | $-0.66 | +17.5% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.64 | $-0.76 | -18.8% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $-0.67 | $-0.64 | +4.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.65 | $-0.63 | +3.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.75 | $-0.62 | +17.3% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.66 | $-0.69 | -4.5% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.66 | $-0.61 | +7.6% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.60 | $-0.63 | -5.0% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.62 | $-0.63 | -1.6% | ✗ MISS |
Latest News
TD Cowen Initiates Coverage On RAPT Therapeutics with Buy Rating
📈 PositiveBenzinga•Dec 18, 2025, 01:06 PM
Barclays Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $56
➖ NeutralBenzinga•Nov 7, 2025, 03:49 PM•Also:
RAPT Therapeutics Q3 EPS $(0.65) Beats $(0.80) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 01:30 PM
Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72
📈 PositiveBenzinga•Nov 3, 2025, 02:11 PM
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72
📈 PositiveBenzinga•Oct 27, 2025, 04:57 PM
Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70
📈 PositiveBenzinga•Oct 27, 2025, 12:11 PM
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial Of Ozureprubart (RPT904) In Patients With Food Allergies
📈 PositiveBenzinga•Oct 27, 2025, 12:07 PM
Reported Earlier, RAPT Therapeutics Prices 8,333,334 Common Shares At $30 Each In $250M Offering To Fund Expansion Of Novel Immunology-Based Therapy Development And Clinical-Stage Programs
➖ NeutralBenzinga•Oct 22, 2025, 07:27 AM
RAPT Therapeutics Announces Common Stock Offering; Terms Not Disclosed
➖ NeutralBenzinga•Oct 21, 2025, 08:02 PM
Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $48
📈 PositiveBenzinga•Oct 21, 2025, 01:08 PM
Barclays Maintains Overweight on RAPT Therapeutics, Raises Price Target to $58
📈 PositiveBenzinga•Oct 21, 2025, 12:47 PM•Also:
Clear Street Maintains Buy on RAPT Therapeutics, Raises Price Target to $60
📈 PositiveBenzinga•Oct 21, 2025, 11:35 AM
JP Morgan Upgrades RAPT Therapeutics to Overweight, Raises Price Target to $55
📈 PositiveBenzinga•Oct 20, 2025, 09:58 PM
RAPT Therapeutics shares are trading higher after the company and Shanghai Jeyou announced topline data from Jeyou's Phase 2 trial of RPT904 as monotherapy in chronic spontaneous urticaria.
📈 PositiveBenzinga•Oct 20, 2025, 12:56 PM
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 20, 2025, 12:25 PM
RAPT Therapeutics And Shanghai Jeyou Announce Topline Data From Jeyou's Phase 2 Trial Of RPT904 As Monotherapy In Chronic Spontaneous Urticaria
➖ NeutralBenzinga•Oct 20, 2025, 12:07 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 20, 2025, 11:55 AM
Reported Sunday, RAPT Therapeutics To Release Phase 2 RPT904 Data Addressing Immune Modulation In Chronic Spontaneous Urticaria During October 20 Webcast
➖ NeutralBenzinga•Oct 20, 2025, 07:33 AM
Barclays Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $35
📈 PositiveBenzinga•Oct 13, 2025, 12:12 PM•Also:
Clear Street Maintains Buy on RAPT Therapeutics, Raises Price Target to $41
📈 PositiveBenzinga•Sep 30, 2025, 12:27 PM
Frequently Asked Questions about RAPT
What is RAPT's current stock price?
RAPT Therapeutics, Inc. (RAPT) is currently trading at $33.81 per share. The stock has moved -0.68% today.
What is the analyst price target for RAPT?
The average analyst price target for RAPT is $57.20, based on 1 analyst.
What sector is RAPT Therapeutics, Inc. in?
RAPT Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RAPT's market cap?
RAPT Therapeutics, Inc. has a market capitalization of $0.56 billion, making it a small-cap company.
Does RAPT pay dividends?
No, RAPT Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
ALMS
Alumis Inc. Common Stock
$11.29
Mkt Cap: $1.2B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
Explore stocks similar to RAPT for comparison